<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>SurvAgent: Hierarchical CoT-Enhanced Case Banking and Dichotomy-Based Multi-Agent System for Multimodal Survival Prediction - Health AI Hub</title>
    <meta name="description" content="SurvAgent is a pioneering hierarchical Chain-of-Thought (CoT)-enhanced multi-agent system designed for explainable and multimodal survival prediction in cancer.">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>SurvAgent: Hierarchical CoT-Enhanced Case Banking and Dichotomy-Based Multi-Agent System for Multimodal Survival Prediction</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.16635v1" target="_blank">2511.16635v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-20
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Guolin Huang, Wenting Chen, Jiaqi Yang, Xinheng Lyu, Xiaoling Luo, Sen Yang, Xiaohan Xing, Linlin Shen
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.CV, cs.CL
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.98 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.16635v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.16635v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">SurvAgent is a pioneering hierarchical Chain-of-Thought (CoT)-enhanced multi-agent system designed for explainable and multimodal survival prediction in cancer. It constructs a rich case bank with detailed CoT reasoning from both whole slide images (WSI) and gene expression data, then employs a dichotomy-based multi-expert agent for progressive inference, demonstrating superior performance over existing methods on TCGA cohorts.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is paramount for cancer prognosis and treatment planning by providing transparent, explainable, and accurate survival predictions, which are essential for fostering clinical trust and facilitating the adoption of AI in oncology practice.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>SurvAgent is an AI system designed to predict patient survival, particularly in cancer, by integrating multimodal medical data (pathology images and gene data). It aims to provide explainable predictions for cancer prognosis and treatment planning, fitting within the domain of precision oncology. Its purpose is to enhance clinical decision support and personalize cancer treatment strategies based on AI-driven insights from complex patient data.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Introduces SurvAgent, the first hierarchical CoT-enhanced multi-agent system specifically for multimodal survival prediction, addressing transparency and data integration challenges.</li>
                    
                    <li>Overcomes limitations of previous pathology agents by integrating multimodal data (WSI and gene expression), improving region-of-interest exploration, and enabling experiential learning from historical cases.</li>
                    
                    <li>Stage 1: WSI-Gene CoT-Enhanced Case Bank Construction employs hierarchical analysis for pathology (Low-Magnification Screening, Cross-Modal Similarity-Aware Patch Mining, Confidence-Aware Patch Mining) and gene-stratified analysis for six functional gene categories.</li>
                    
                    <li>Stage 1 outputs structured reports with complete CoT reasoning for both pathology and gene data, serving as a comprehensive knowledge base for experiential learning.</li>
                    
                    <li>Stage 2: Dichotomy-Based Multi-Expert Agent Inference retrieves similar cases using Retrieval Augmented Generation (RAG) and integrates multimodal reports with expert predictions through progressive interval refinement.</li>
                    
                    <li>Achieves superior performance on multimodal survival prediction across five diverse TCGA cohorts compared to conventional methods, proprietary MLLMs, and existing medical agents.</li>
                    
                    <li>Establishes a new paradigm for explainable AI in precision oncology, offering transparent insights crucial for cancer prognosis and personalized treatment planning.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>SurvAgent operates in two stages. The first stage, WSI-Gene CoT-Enhanced Case Bank Construction, involves hierarchical analysis of pathology images through Low-Magnification Screening, Cross-Modal Similarity-Aware Patch Mining, and Confidence-Aware Patch Mining, alongside Gene-Stratified analysis across six functional gene categories. Both processes generate structured reports containing complete Chain-of-Thought reasoning for experiential learning. The second stage, Dichotomy-Based Multi-Expert Agent Inference, utilizes Retrieval Augmented Generation (RAG) to retrieve similar cases and integrates the multimodal reports with expert predictions via progressive interval refinement.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>SurvAgent consistently demonstrates superior performance in multimodal survival prediction across five diverse TCGA cohorts. It significantly outperforms conventional survival analysis methods, proprietary multimodal large language models (MLLMs), and other medical agents, effectively integrating multimodal data (WSI and gene expression) while providing transparent and explainable predictions.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The ability of SurvAgent to deliver accurate, transparent, and explainable multimodal survival predictions holds significant promise for enhancing clinical decision-making in cancer. This can lead to more personalized and effective treatment planning, improve patient risk stratification, and build greater clinician trust in AI-driven tools within precision oncology settings.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract addresses the limitations of *existing* methods that SurvAgent aims to overcome (inability to integrate multimodal data, ineffective region-of-interest exploration, and lack of experiential learning). No specific limitations or caveats of SurvAgent itself are explicitly mentioned in the provided abstract.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly mentioned in the abstract.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pathology</span>
                    
                    <span class="tag">Genomics</span>
                    
                    <span class="tag">Prognostics</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Survival analysis</span>
                    
                    <span class="tag tag-keyword">Multi-agent system</span>
                    
                    <span class="tag tag-keyword">Chain-of-Thought (CoT)</span>
                    
                    <span class="tag tag-keyword">Multimodal prediction</span>
                    
                    <span class="tag tag-keyword">Whole Slide Imaging (WSI)</span>
                    
                    <span class="tag tag-keyword">Gene expression</span>
                    
                    <span class="tag tag-keyword">Cancer prognosis</span>
                    
                    <span class="tag tag-keyword">Explainable AI</span>
                    
                    <span class="tag tag-keyword">Precision oncology</span>
                    
                    <span class="tag tag-keyword">Case-based reasoning</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Survival analysis is critical for cancer prognosis and treatment planning, yet existing methods lack the transparency essential for clinical adoption. While recent pathology agents have demonstrated explainability in diagnostic tasks, they face three limitations for survival prediction: inability to integrate multimodal data, ineffective region-of-interest exploration, and failure to leverage experiential learning from historical cases. We introduce SurvAgent, the first hierarchical chain-of-thought (CoT)-enhanced multi-agent system for multimodal survival prediction. SurvAgent consists of two stages: (1) WSI-Gene CoT-Enhanced Case Bank Construction employs hierarchical analysis through Low-Magnification Screening, Cross-Modal Similarity-Aware Patch Mining, and Confidence-Aware Patch Mining for pathology images, while Gene-Stratified analysis processes six functional gene categories. Both generate structured reports with CoT reasoning, storing complete analytical processes for experiential learning. (2) Dichotomy-Based Multi-Expert Agent Inference retrieves similar cases via RAG and integrates multimodal reports with expert predictions through progressive interval refinement. Extensive experiments on five TCGA cohorts demonstrate SurvAgent's superority over conventional methods, proprietary MLLMs, and medical agents, establishing a new paradigm for explainable AI-driven survival prediction in precision oncology.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>20 pages</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>